Individualizing care for patients with gallbladder cancer

The rarity and lack of Level I Evidence compromise our ability to care for patients with gallbladder cancer. NCDB cohort study of with resected Stage Groups IB-IVA gallbladder adenocarcinoma between 2004 and 2018. Patients were included. 8484 patients were included, median survival was 29.8 (CI 28.6...

Full description

Saved in:
Bibliographic Details
Published in:Surgical oncology 2024-12, Vol.57, p.102163, Article 102163
Main Authors: Nicolais, Laura M., Fitzgerald, Timothy L.
Format: Article
Language:English
Subjects:
Adenocarcinoma
Adenocarcinoma - mortality
Adenocarcinoma - pathology
Adenocarcinoma - therapy
Adjuvant therapy
Aged
Chemoradiation
Chemoradiotherapy
Chemotherapy
Chemotherapy, Adjuvant
Cholecystectomy
Cohort Studies
Female
Follow-Up Studies
Gallbladder
Gallbladder Neoplasms - mortality
Gallbladder Neoplasms - pathology
Gallbladder Neoplasms - therapy
Humans
Male
Middle Aged
Neoplasm Staging
Precision Medicine
Prognosis
Retrospective Studies
Surgery
Survival Rate
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The rarity and lack of Level I Evidence compromise our ability to care for patients with gallbladder cancer. NCDB cohort study of with resected Stage Groups IB-IVA gallbladder adenocarcinoma between 2004 and 2018. Patients were included. 8484 patients were included, median survival was 29.8 (CI 28.6–31.2); Stage IB: 67.0, Stage II: 36.6, and Stage III/IVA 18.4 months. A survival benefit was noted for surgery beyond cholecystectomy (Stage IB 105 vs. 36 months, HR 0.56, p 
ISSN:0960-7404
1879-3320
1879-3320
DOI:10.1016/j.suronc.2024.102163